Raymond Cho
University of California, San Francisco · Baylor College of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Raymond Cho as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:14 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07352566 · Utilization of a Microdevice for Psoriasis and Atopic DermatitisUniversity of California, San Francisco · not yet recruiting · Psoriasis, Atopic Dermatitis · principal investigator
- Ph4NCT05858645 · Correction of Psoriatic T Cell Signatures by DeucravacitinibUniversity of California, San Francisco · recruiting · Psoriasis Vulgaris · principal investigator
- Ph4NCT05858619 · Molecular Signatures of Cutaneous Dupilumab ResponseUniversity of California, San Francisco · recruiting · Atopic Dermatitis · principal investigator
- Ph4NCT05858632 · Immune Spatial Features of Guselkumab Cutaneous ResponseUniversity of California, San Francisco · recruiting · Psoriasis of Scalp · principal investigator
- Ph4NCT05390515 · Psoriatic Immune Response to TildrakizumabUniversity of California, San Francisco · recruiting · Psoriasis Vulgaris · principal investigator
- Ph4NCT04541329 · Predicting Inflammatory Skin Disease Response to IL-23 BlockadeUniversity of California, San Francisco · completed · Psoriasis Vulgaris · principal investigator
- N/ANCT02975973 · Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in SchizophreniaBaylor College of Medicine · completed · Schizophrenia, Psychosis · principal investigator
- N/ANCT02739347 · Non-Invasive Direct Current Stimulation for Cognition in SchizophreniaBaylor College of Medicine · terminated · Schizophrenia, Psychosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 7 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Defining and treating genetic abnormalities in psoriasis/atopic dermatitis-overlap dermatosesR01AR084006 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2025 to 2026 · $545,401 awarded in 2026Same name and institution; not confirmed by an ID
- Investigating single-T cell atopic gene networks in Asian and Hispanic genetic backgroundsR56AR082484 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2024 · $343,904 awarded in 2024Same name and institution; not confirmed by an ID
- TMS-EEG investigation of prefrontal cortical excitability in depression and rTMS treatment responseR21MH119441 · NIMH · BAYLOR COLLEGE OF MEDICINE · fiscal years 2020 · $204,778 awarded in 2020Same name and institution; not confirmed by an ID
- Prefrontal cortical engagement and clinical effects of non-invasive direct current stimulation for cognitive control impairments in schizophreniaR61MH110044 · NIMH · BAYLOR COLLEGE OF MEDICINE · fiscal years 2016 to 2017 · $425,430 awarded in 2017Same name and institution; not confirmed by an ID
- Integrated analysis of Notch pathway loss-of-function in epithelial tumorigenesisK08CA169865 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2012 to 2015 · $126,090 awarded in 2015Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:14 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- 1,155 citationsRCR 23.9
- Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial.Arch Gen Psychiatry · 2010243 citationsRCR 7.6
- Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.Am J Psychiatry · 2008240 citationsRCR 6.4
- 93 citationsRCR 3.1
- A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.J Psychopharmacol · 201651 citationsRCR 2.1
- Dopamine and gamma band synchrony in schizophrenia--insights from computational and empirical studies.Eur J Neurosci · 201239 citationsRCR 1.3
- Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood Adv · 202238 citationsRCR 2.9
- 35 citationsRCR 1.7
- Oral hydration and alkalinization is noninferior to intravenous therapy for prevention of contrast-induced nephropathy in patients with chronic kidney disease.J Interv Cardiol · 201032 citationsRCR 1.1
- 28 citationsRCR 6.8